abbott laboratories (ABT:New York)
Transactions by ABBOTT LABORATORIES (ABT) in the last 6 months
Mylan, Inc. (NasdaqGS:MYL) entered into a business transfer agreement to acquire non-U.S. developed markets specialty and branded generics business of Abbott Laboratories (NYSE:ABT) for approximately $5.3 billion on July 13, 2014. The assets are being acquired on a debt-free basis. In the transaction, Abbott will transfer the assets to Mylan in consideration for 105 million Mylan ordinary shares, representing 21% stake and Mylan will hold 71% stake. Under the agreement, ...
Abbott Laboratories (NYSE:ABT) signed a definitive agreement to acquire GardenHills OOO for approximately $630 million on June 23, 2014. Under the terms of the agreement, Abbott will acquire Garden Hills, the holding company that currently owns a controlling interest in Veropharm, for between approximately $395 million to $495 million depending on GardenHills' share ownership of Veropharm at time of close. If Garden Hills owns 100% of the shares of Veropharm at that ...
Aviir, Inc. filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the Central District of California on January 27, 2014. The debtor listed its assets of $3.70 million and liabilities of $13.62 million. The largest unsecured creditors include Bay City Capital Fund IV Co-Investment Fund, L.P., Merck Global Health Innovation Fund, LLC, Abbott Laboratories, Paragon Biomedical, Inc., Quansys Biosciences, Inc., Stradling Yocca Carlson & ...
Bay City Capital Fund IV Co-Investment Fund, L.P
Global Health Innovation Fund, LLC
Paragon Biomedical, Inc.
Quansys Biosciences, Inc.
Stradling Yocca Carlson & Rauth, P.C.
|AbbVie Inc||$54.48 USD||+0.43|
|Bristol-Myers Squibb Co||$49.32 USD||+0.20|
|Danaher Corp||$75.61 USD||-0.19|
|Eli Lilly & Co||$64.25 USD||+0.53|
|Medtronic Inc||$63.37 USD||+0.66|
|View Industry Companies|